Meta Platforms has dropped another leg lower — the recovery narrative that looked possible at $599 last week is gone, with the stock now at $543.67 after a 9.3% weekly decline and 4.4% fall on Tuesday alone.
The shift in tone since the August 17 report is meaningful. That note flagged the $1.4 trillion social media addiction trial as a new headwind. This week, the market has repriced that risk more aggressively. The stock is now down 15.8% over the past month, sitting roughly $55 below where it was when the trial entered the conversation. The post-Q3 earnings washout low near $557 is no longer support — it has been broken cleanly. At $543.67, META trades 38% below the Street's mean price target of $754, a gap that reflects either a deeply mispriced stock or a market that has decided the analyst community is not yet accounting for legal tail risk.
The options market tells a story that stands apart from the price action. Positioning remains unusually call-heavy — the put/call ratio is 0.43, actually near its 52-week low of 0.43, and running about 1.5 standard deviations below its 20-day average of 0.45. That's the opposite of what you'd expect from investors hedging into a legal overhang. It suggests options participants are either fading the selloff with call exposure or have not yet rotated into defensive puts despite back-to-back weeks of double-digit losses. The short-side tells the same low-conviction story: SI is 1.45% of float with borrow availability effectively unlimited and cost to borrow at 0.25%. There is no short-seller pressure here — this is pure long liquidation.
The Street has held its bullish ratings intact but the credibility of current targets is increasingly in question. Following the July 30 Q3 earnings drop of 9.2%, Goldman Sachs, UBS, Citigroup, Baird, TD Cowen and a broad sweep of other firms trimmed targets in unison while keeping Buy or Outperform ratings. Goldman cut from $815 to $725, UBS moved from $766 to $715, and Susquehanna made the largest reduction — from $900 to $650. Even after those cuts, the consensus mean of $754 implies 39% upside from current levels. The forward earnings growth factor score ranks in the 86th percentile, and the EV/EBITDA multiple has compressed to 9x, which is modest for a business of this quality. The bear case centres on ad revenue vulnerability to regulatory pressure, privacy mandates, and platform competition. The bull case rests on AI monetisation optionality and a nearly 4-billion-user base with ad targeting that remains best-in-class. Neither camp has changed its argument — the trial has simply added a variable that neither had modelled.
Among the closest peers, SNAP fell 7.3% on the week and RDDT was flat, so this is not a sector-wide rotation — META is absorbing idiosyncratic selling. BIDU was the hardest hit in the peer group at -14.2%, though on separate macro pressures. Institutional holders including BlackRock, Capital Research, and State Street all added shares through July 31, suggesting large passive and active money was still buying the Q3 dip — but those positions were built at prices well above where the stock now trades.
Earnings are next due October 28. The last two prints each produced single-day drops exceeding 5%, meaning the market has already been conditioned to fade results. The question heading into that date is whether the legal proceedings — and any damages guidance or settlement signals — become the dominant variable rather than the advertising revenue or AI capex trajectory that the Street's models are built around.
See the live data behind this article on ORTEX.
Open META on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
